.Pharmacolibrary.Drugs.R_RespiratorySystem.R03D_OtherSystemicDrugsForObstructiveAirwayDiseases.R03DX10_Benralizumab.Benralizumab

Information

Benralizumab is a humanized monoclonal antibody targeting the interleukin-5 receptor alpha (IL-5Rα) on eosinophils, leading to their depletion. It is used for the treatment of severe eosinophilic asthma and is approved for this indication in many countries.

Pharmacokinetics

Population pharmacokinetics in adults and adolescents (12–75 years) with severe eosinophilic asthma following subcutaneous administration.

References

1. Wang, B, et al., & Roskos, LK (2017). Population Pharmacokinetics and Pharmacodynamics of Benralizumab in Healthy Volunteers and Patients With Asthma. CPT: pharmacometrics & systems pharmacology 6(4) 249–257. DOI:10.1002/psp4.12160 PUBMED:https://pubmed.ncbi.nlm.nih.gov/28109128

2. Yan, L, et al., & Roskos, LK (2019). Population Pharmacokinetic Modeling of Benralizumab in Adult and Adolescent Patients with Asthma. Clinical pharmacokinetics 58(7) 943–958. DOI:10.1007/s40262-019-00738-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/30854591

Revisions

• 06/2025 initial generated model